Vistagen Therapeutics Inc (NAS:VTGN)
$ 3.19 0.04 (1.27%) Market Cap: 86.31 Mil Enterprise Value: -21.37 Mil PE Ratio: 0 PB Ratio: 0.81 GF Score: 29/100

Q2 2023 VistaGen Therapeutics Inc Earnings Call Transcript

Nov 10, 2022 / 10:00PM GMT
Release Date Price: $3.9 (+15.45%)
Operator

Good day, and welcome to the VistaGen Second Quarter Fiscal Year 2023 Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mark Flather, Vice President and Investor Relations. Please go ahead, sir.

Mark Flather
VistaGen Therapeutics, Inc. - VP of IR

Thank you, Jenny. Hello, and welcome to VistaGen's conference call covering our second quarter of fiscal year 2023 Financial Results and Business Update. I'm Mark Flather, Vice President of Investor Relations at VistaGen. Thank you for joining us today, and welcome to our stockholders, analysts and anyone taking an interest in VistaGen.

Joining me today are Shawn Singh, our Chief Executive Officer; and Jerry Dotson, our Chief Financial Officer. The format for this call will consist of prepared remarks from management, followed by a brief opportunity from questions from sell-side analysts. This call is being webcasted and will be available for replay. The link to access the replay can be found in the Investors IR Calendar section of our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot